THE PREVALENCE OF CARDIOMETABOLIC RISK FACTORS AND THE TEN-YEAR RISK OF FATAL CARDIOVASCULAR EVENTS IN PATIENTS WITH SCHIZOPHRENIA AND RELATED PSYCHOTIC DISORDERS

被引:0
作者
Protopopova, Dita [1 ,2 ]
Masopust, Jiri [2 ]
Maly, Radovan [3 ]
Valis, Martin [4 ]
Bazant, Jan [2 ]
机构
[1] Univ Hosp, Dept Psychiat, Hradec Kralove 50005, Czech Republic
[2] Charles Univ Prague, Fac Med, Dept Psychiat, Hradec Kralove, Czech Republic
[3] Charles Univ Prague, Fac Med, Dept Internal Med, Hradec Kralove, Czech Republic
[4] Univ Hosp, Emergency Dept, Hradec Kralove 50005, Czech Republic
关键词
schizophrenia; cardiovascular; risk factor; mortality; METABOLIC SYNDROME; ANTIPSYCHOTICS; DISEASE; POPULATION;
D O I
暂无
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Background: People suffering from schizophrenia have a significantly shorter lifespan compared to the general population. The majority of deaths are caused by physical diseases, including cardiovascular events. The aim of this cross-sectional study was to predict the risk of premature cardiovascular mortality and assess the prevalence of cardiometabolic risk factors in a sample of Czech patients with schizophrenia and related psychoses. Subjects and methods: We reviewed data from 129 subjects treated in an outpatient clinic that specialised in psychoses. The main collected variables included basic physical parameters (height, weight, waist circumference, blood pressure), smoking habits, laboratory data (glucose level, serum lipid level) and an electrocardiograph (ECG). We calculated the ten-year risk of fatal cardiovascular events using the Systematic Coronary Risk Evaluation (SCORE) chart. Results: The most prevalent risk factors were being overweight (70% of patients had a BMI over 25), dyslipidaemia (70% of patients) and smoking (43% of patients). According to the SCORE diagram, there was a high risk of fatal cardiovascular events over a ten-year period in 10% of the study group. The percentage was even higher (24%) when the latest European guidelines for cardiovascular disease prevention were used to calculate the risk. Conclusions: Our outcomes indicate even higher cardiometabolic morbidity rates in patients with psychoses than those referenced in the literature.
引用
收藏
页码:307 / 313
页数:7
相关论文
共 24 条
  • [1] [Anonymous], 2004, J CLIN PSYCHIAT, V65, P267
  • [2] Prevalence and awareness of cardiovascular risk factors in patients with schizophrenia: A cross-sectional study in a low cardiovascular disease risk geographical area
    Bernardo, M.
    Canas, F.
    Banegas, J. R.
    Casademont, J.
    Riesgo, Y.
    Varela, C.
    [J]. EUROPEAN PSYCHIATRY, 2009, 24 (07) : 431 - 441
  • [3] Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: Results of the CLAMORS Study
    Bobes, Julio
    Arango, Celso
    Aranda, Pedro
    Carmena, Rafael
    Garcia-Garcia, Margarida
    Rejas, Javier
    [J]. SCHIZOPHRENIA RESEARCH, 2007, 90 (1-3) : 162 - 173
  • [4] Prevalence of cardiovascular risk factors and disease in people with schizophrenia: A population-based study
    Bresee, Lauren C.
    Majumdar, Sumit R.
    Patten, Scott B.
    Johnson, Jeffrey A.
    [J]. SCHIZOPHRENIA RESEARCH, 2010, 117 (01) : 75 - 82
  • [5] Cifkova R, 2005, SUPPLEMENTUM COR VAS, V47, P3
  • [6] Longitudinal trends in major cardiovascular risk factors in the Czech population between 1985 and 2007/8. Czech MONICA and Czech post-MONICA
    Cifkova, Renata
    Skodova, Zdenka
    Bruthans, Jan
    Adamkova, Vera
    Jozifova, Marie
    Galovcova, Marketa
    Wohlfahrt, Peter
    Krajcoviechova, Alena
    Poledne, Rudolf
    Stavek, Petr
    Lanska, Vera
    [J]. ATHEROSCLEROSIS, 2010, 211 (02) : 676 - 681
  • [7] Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
    Cleeman, JI
    Grundy, SM
    Becker, D
    Clark, LT
    Cooper, RS
    Denke, MA
    Howard, WJ
    Hunninghake, DB
    Illingworth, DR
    Luepker, RV
    McBride, P
    McKenney, JM
    Pasternak, RC
    Stone, NJ
    Van Horn, L
    Brewer, HB
    Ernst, ND
    Gordon, D
    Levy, D
    Rifkind, B
    Rossouw, JE
    Savage, P
    Haffner, SM
    Orloff, DG
    Proschan, MA
    Schwartz, JS
    Sempos, CT
    Shero, ST
    Murray, EZ
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19): : 2486 - 2497
  • [8] Estimation of ten-year risk of fatal cardiovascular disease in Europe:: the SCORE project
    Conroy, RM
    Pyörälä, K
    Fitzgerald, AP
    Sans, S
    Menotti, A
    De Backer, G
    De Bacquer, D
    Ducimetière, P
    Jousilahti, P
    Keil, U
    Njolstad, I
    Oganov, RG
    Thomsen, T
    Tunstall-Pedoe, H
    Tverdal, A
    Wedel, H
    Whincup, P
    Wilhelmsen, L
    Graham, IM
    [J]. EUROPEAN HEART JOURNAL, 2003, 24 (11) : 987 - 1003
  • [9] Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study
    Daumit, Gail L.
    Goff, Donald C.
    Meyer, Jonathan M.
    Davis, Vicki G.
    Nasrallah, Henry A.
    McEvoy, Joseph P.
    Rosenheck, Robert
    Davis, Sonia M.
    Hsiao, John K.
    Stroup, T. Scott
    Lieberman, Jeffrey A.
    [J]. SCHIZOPHRENIA RESEARCH, 2008, 105 (1-3) : 175 - 187
  • [10] Epidemiological study for the evaluation of metabolic disorders in patients with schizophrenia: The METEOR Study
    De Hert, M.
    Falissard, B.
    Mauri, M.
    Shaw, K.
    Wetterling, T.
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2008, 18 : S444 - S445